| Dr Bita Arabshahi, MD | |
|
8505 Arlington Blvd, Suite 100, Fairfax, VA 22031-4621 | |
| (703) 970-2600 | |
| (703) 970-2620 |
| Full Name | Dr Bita Arabshahi |
|---|---|
| Gender | Female |
| Speciality | Pediatrics - Pediatric Rheumatology |
| Location | 8505 Arlington Blvd, Fairfax, Virginia |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1942213962 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 2080P0216X | Pediatrics - Pediatric Rheumatology | 0101240106 (Virginia) | Primary |
| Entity Name | Inova Health Care Services |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1952320061 PECOS PAC ID: 2466351093 Enrollment ID: O20040102000644 |
News Archive
China Medical Technologies, Inc. (the "Company"), a leading China-based medical device company that develops, manufactures and markets advanced in-vitro diagnostic products, today announced its unaudited financial results for the second fiscal quarter ended September 30, 2009 ("2Q FY2009"). The Company's 2009 fiscal year ends on March 31, 2010 ("FY2009").
STAAR Surgical Company, a leading developer, manufacturer and marketer of minimally invasive ophthalmic products, today announced the Visian Implantable Collamer Lens (ICL), and new Visian ICL with CentraFLOW technology utilizing the KS-AquaPORT, were featured prominently in twice as many presentations at the 2011 Congress of European Society of Cataract and Refractive Surgeons (ESCRS) as those on the ICL during last year's Congress.
According to experts a simple DNA test for Down syndrome could save nearly all pregnant women from invasive tests like amniocentesis. Usually 3% to 5% of pregnant women in the UK or some 30,000 women have to undergo invasive tests like amniocentesis that increases the risk of miscarriage to 1%. The new DNA blood test could bring this down to 0.1%, according to a study in the British Medical Journal.
BioDelivery Sciences International, Inc. announced that it has entered into a license and supply agreement with Kunwha Pharmaceutical Co., Ltd., for the exclusive rights to develop and commercialize BEMA Fentanyl (marketed as ONSOLIS in the U.S.) in the Republic of Korea. The agreement results in potential milestone payments to BDSI of up to $1,275,000, which includes an upfront payment of $300,000. In addition, BDSI will receive an ongoing royalty based on net sales.
› Verified 5 days ago
| Entity Name | Pediatric Specialists Of Virginia Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1699119818 PECOS PAC ID: 7719110154 Enrollment ID: O20140509000026 |
News Archive
China Medical Technologies, Inc. (the "Company"), a leading China-based medical device company that develops, manufactures and markets advanced in-vitro diagnostic products, today announced its unaudited financial results for the second fiscal quarter ended September 30, 2009 ("2Q FY2009"). The Company's 2009 fiscal year ends on March 31, 2010 ("FY2009").
STAAR Surgical Company, a leading developer, manufacturer and marketer of minimally invasive ophthalmic products, today announced the Visian Implantable Collamer Lens (ICL), and new Visian ICL with CentraFLOW technology utilizing the KS-AquaPORT, were featured prominently in twice as many presentations at the 2011 Congress of European Society of Cataract and Refractive Surgeons (ESCRS) as those on the ICL during last year's Congress.
According to experts a simple DNA test for Down syndrome could save nearly all pregnant women from invasive tests like amniocentesis. Usually 3% to 5% of pregnant women in the UK or some 30,000 women have to undergo invasive tests like amniocentesis that increases the risk of miscarriage to 1%. The new DNA blood test could bring this down to 0.1%, according to a study in the British Medical Journal.
BioDelivery Sciences International, Inc. announced that it has entered into a license and supply agreement with Kunwha Pharmaceutical Co., Ltd., for the exclusive rights to develop and commercialize BEMA Fentanyl (marketed as ONSOLIS in the U.S.) in the Republic of Korea. The agreement results in potential milestone payments to BDSI of up to $1,275,000, which includes an upfront payment of $300,000. In addition, BDSI will receive an ongoing royalty based on net sales.
› Verified 5 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Bita Arabshahi, MD 3300 Gallows Rd, Physician Billing, Falls Church, VA 22042-3307 Ph: (703) 776-2545 | Dr Bita Arabshahi, MD 8505 Arlington Blvd, Suite 100, Fairfax, VA 22031-4621 Ph: (703) 970-2600 |
News Archive
China Medical Technologies, Inc. (the "Company"), a leading China-based medical device company that develops, manufactures and markets advanced in-vitro diagnostic products, today announced its unaudited financial results for the second fiscal quarter ended September 30, 2009 ("2Q FY2009"). The Company's 2009 fiscal year ends on March 31, 2010 ("FY2009").
STAAR Surgical Company, a leading developer, manufacturer and marketer of minimally invasive ophthalmic products, today announced the Visian Implantable Collamer Lens (ICL), and new Visian ICL with CentraFLOW technology utilizing the KS-AquaPORT, were featured prominently in twice as many presentations at the 2011 Congress of European Society of Cataract and Refractive Surgeons (ESCRS) as those on the ICL during last year's Congress.
According to experts a simple DNA test for Down syndrome could save nearly all pregnant women from invasive tests like amniocentesis. Usually 3% to 5% of pregnant women in the UK or some 30,000 women have to undergo invasive tests like amniocentesis that increases the risk of miscarriage to 1%. The new DNA blood test could bring this down to 0.1%, according to a study in the British Medical Journal.
BioDelivery Sciences International, Inc. announced that it has entered into a license and supply agreement with Kunwha Pharmaceutical Co., Ltd., for the exclusive rights to develop and commercialize BEMA Fentanyl (marketed as ONSOLIS in the U.S.) in the Republic of Korea. The agreement results in potential milestone payments to BDSI of up to $1,275,000, which includes an upfront payment of $300,000. In addition, BDSI will receive an ongoing royalty based on net sales.
› Verified 5 days ago
Ho Chung Tu, M.D. Pediatrics Medicare: Not Enrolled in Medicare Practice Location: 3913 Old Lee Highway, Office No 31b, Fairfax, VA 22030 Phone: 703-359-0245 Fax: 928-436-3339 | |
Dr. Lindsey Waldman, Pediatrics Medicare: Medicare Enrolled Practice Location: 3023 Hamaker Ct, Fairfax, VA 22031 Phone: 703-839-8797 | |
Dr. Laura E. Byrnes, M.D. Pediatrics Medicare: Medicare Enrolled Practice Location: 3650 Joseph Siewick Dr, Ste 101, Fairfax, VA 22033 Phone: 703-391-0900 Fax: 703-391-2919 | |
Dr. Julie-ann M Crewalk, M.D. Pediatrics Medicare: Not Enrolled in Medicare Practice Location: 2730-c Prosperity Avenue, Fairfax, VA 22031 Phone: 703-226-2280 Fax: 703-752-1713 | |
Sandy L. Chung, M.D. Pediatrics Medicare: Medicare Enrolled Practice Location: 3650 Joseph Siewick Dr, Ste 101, Fairfax, VA 22033 Phone: 703-391-0900 Fax: 703-391-2919 | |
Dr. James R Baugh, M.D. Pediatrics Medicare: Not Enrolled in Medicare Practice Location: 3020 Hamaker Ct, Suite 200, Fairfax, VA 22031 Phone: 703-573-2432 Fax: 703-280-9350 | |
Benjamin Isaac Enav, M.D. Pediatrics Medicare: Medicare Enrolled Practice Location: 2700 Prosperity Ave, Suite 260, Fairfax, VA 22031 Phone: 571-314-0444 Fax: 855-237-3628 |